Compare Inovio Pharmaceuticals Inc (INO) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs LTC Properties Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while LTC Properties Inc trades at $42 (market cap $2.15B). The key difference: LTC Properties Inc is far larger — about 24.1× Inovio Pharmaceuticals Inc's market cap, and LTC Properties Inc pays a 5.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LTC | |
|---|---|---|
Market Cap | $89.27M | $2.15B |
Sector | Health | Real Estate |
52-Week High | $2.87 | $41.92 |
52-Week Low | $1.05 | $33.98 |
Enterprise Value | $60.28M | $2.99B |
Dividend Yield | — | 5.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
LTC Properties trades at $41.92, up 0.41% with a bullish technical outlook. The REIT shows strong fundamentals with 2025 revenue of $263M and net income of $118M, supported by a 67.3% gross margin. Recent acquisitions expand its SHOP portfolio, targeting demographic trends in senior housing. Analyst sentiment is mixed with 27% buy ratings amid recent earnings misses.
Outlook: Growth driven by strategic acquisitions and aging demographics, but execution risks and debt levels warrant caution. Near-term focus on Q2 2026 earnings (expected EPS $0.48) as a key catalyst. Dividend yield of ~5.4% provides income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
